•• Dhillon S, et al. Drugs. 2021;81(7):867–74. https://doi.org/10.1007/s40265-021-01508-y. This article explains the mechanism of action of trilaciclib and the potential limitation of its use.

CAS  Article  PubMed  Google Scholar 

•• Mohile SG, Mohamed MR, Xu H, Culakova E, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894–904. https://doi.org/10.1016/S0140-6736(21)01789-X. Important for two reasons: it demonstrates the feasibility of geriatric assessment in the clinical practice of oncology and the ability of the geriatric assessment to ameliorate the risks of chemotherapy.

Article  PubMed  Google Scholar 

Li D, Sun CL, Kim H, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):e214158. https://doi.org/10.1001/jamaoncol.2021.4158.

Article  PubMed  Google Scholar 

Balducci L, Fossa SD. Rehabilitation of older cancer patients. Acta Oncol. 2013;52(2):233–8. https://doi.org/10.3109/0284186X.2012.744142.

Article  PubMed  Google Scholar 

https://cancercontrol.cancer.gov/ocs/statistics#footnote1

Boreskie KF, Hay JL, Boreskie PE, Arora RC, Duhamel TA. Frailty-aware care: giving value to frailty assessment across different healthcare settings. BMC Geriatr. 2022;22(1):13. https://doi.org/10.1186/s12877-021-02722-9.

Article  PubMed  PubMed Central  Google Scholar 

Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev. 2005;31(5):380–402. https://doi.org/10.1016/j.ctrv.2005.04.012.

Article  PubMed  Google Scholar 

Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–47. https://doi.org/10.1200/JCO.2018.78.8687.

Article  PubMed  PubMed Central  Google Scholar 

Hirakawa T, Yamaguchi H, Yokose N, et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89(9):897–904. https://doi.org/10.1007/s00277-010-0956-7.

CAS  Article  PubMed  Google Scholar 

Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10–5. https://doi.org/10.1056/NEJM198101013040103.

CAS  Article  PubMed  Google Scholar 

Beguin Y. Erythropoietin and platelet production. Haematologica. 1999;84(6):541–7.

CAS  PubMed  Google Scholar 

Orkin SH, Morrison SJ. Stem-cell competition. Nature. 2002;418(6893):25–7. https://doi.org/10.1038/418025a.

CAS  Article  PubMed  Google Scholar 

•• Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219–26. This reference describes the nexus of chemotherapy, growth factors, and MDS/AML.

CAS  Article  Google Scholar 

Eskelund CW, Husby S, Favero F, et al. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after the end of chemotherapy in patients with MCL. Blood. 2020;135:2000–4.

Article  Google Scholar 

Ferrucci L, Balducci L. Anemia of aging: the role of chronic inflammation and cancer. Semin Hematol. 2008;45(4):242–9. https://doi.org/10.1053/j.seminhematol.2008.06.001.

Article  PubMed  PubMed Central  Google Scholar 

Hardy SE, Studenski SA. Fatigue and function over 3 years among older adults. J Gerontol A Biol Sci Med Sci. 2008;63(12):1389–92. https://doi.org/10.1093/gerona/63.12.1389.

Article  PubMed  Google Scholar 

Hardy SE, Studenski SA. Fatigue predicts mortality in older adults. J Am Geriatr Soc. 2008;56(10):1910–4. https://doi.org/10.1111/j.1532-5415.2008.01957.x.

Article  PubMed  PubMed Central  Google Scholar 

Al-Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437–48. https://doi.org/10.1080/17474086.2021.1924053.

CAS  Article  PubMed  Google Scholar 

Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer. 2004;101(11):2675–80. https://doi.org/10.1002/cncr.20688.

Article  PubMed  Google Scholar 

Ocheni S, Ibegbulam O, Aguwa E, Madu K. Pattern of CD4 T-lymphocyte values in cancer patients on cytotoxic therapy. Ann Med Health Sci Res. 2013;3(4):498–503. https://doi.org/10.4103/2141-9248.122054.

Article  PubMed  PubMed Central  Google Scholar 

• GBrown TJ, Gupta A. Management of cancer therapy-associated oral mucositis. JCO Oncol Pract. 2020;16(3):103–9. https://doi.org/10.1200/JOP.19.00652. Review of current management of chemotherapy-induced mucositis.

Article  Google Scholar 

Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50–9. https://doi.org/10.1016/S1470-2045(12)70553-3.

CAS  Article  PubMed  Google Scholar 

Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937–45.

CAS  PubMed  Google Scholar 

Andric Z, Ceric T, Turic M, et al. A phase I b study of the dual MDMX/MDM2 inhibitor for prevention of chemotherapy induced myelosuppression. Presented at the virtual European Society of Medical Oncology congress September 16 2021 #1654 AP. Ann Oncol. 2021;32(suppl_5):S1164–74. https://doi.org/10.1016/annonc/annonc68.

Article  Google Scholar 

Weiss JM, Csoszi T, Maglakelidze M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019;30(10):1613–21. https://doi.org/10.1093/annonc/mdz278.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled Phase II trial. Int J Cancer. 2020;148(10):2557–70. https://doi.org/10.1002/ijc.33453.

CAS  Article  Google Scholar 

Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–65. https://doi.org/10.1007/s12325-020-01538-0.

CAS  Article  PubMed  Google Scholar 

Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020;8(2):e000847. https://doi.org/10.1136/jitc-2020-000847.

Article  PubMed  PubMed Central  Google Scholar 

•• Hussein M, Maglakelidze M, Richards DA, et al. Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res. 2021;13:6207–18. https://doi.org/10.2147/CMAR.S313045. This article presents the pooled analysis of three studies and demonstrates the ability of trilaciclib to prevent thrombocytopenia and anemia in addition to neutropenia.

Article  PubMed  PubMed Central  Google Scholar 

Weiss J, Goldschmidt J, Andric, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449–60. https://doi.org/10.1016/j.cllc.2021.03.010.

CAS  Article  PubMed  Google Scholar 

Gheradini et al. Temporary cell cycle arrest by ALRN-6924 selectively protects human scalp hair follicles and their epithelial cells from taxane-induced toxicity. Presented at the 2022 Society for Investigative Dermatology Annual Meeting

• Heckler M, Ali LR, Clancy-Thompson E, et al. Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021;11(10):2564–81. https://doi.org/10.1158/2159-8290.CD-20-1540. Increase production of T-cell clones may be beneficial for treatment with immunotherapy.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Zhou X, Singh M, Sanz Santos G, et al. Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity. Cancer Discov. 2021:candisc.1741.2020. https://doi.org/10.1158/2159-8290.CD-20-1741.

Abraham I, Onyekwere U, Deniz B, et al. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. J Med Econ. 2021;24(sup1):71–83. https://doi.org/10.1080/13696998.2021.2014163.

Article  PubMed  Google Scholar 

Lyman GH, Kuderer NM, Aapro M. Improving outcomes of chemotherapy: established and novel options for myeloprotection in the COVID-19 era. Front Oncol. 2021;11:697908. https://doi.org/10.3389/fonc.2021.697908.

Article  PubMed  PubMed Central  Google Scholar 

Hurria A, Dale W, Mooney M, et al. Cancer and aging research group. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587–94. https://doi.org/10.1200/JCO.2013.55.0418.

Article  PubMed  PubMed Central  Google Scholar 

Hurria A, Levit LA, Dale W, Mohile SG, et al. American Society of Clinical Oncology. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement. J Clin Oncol. 2015;33(32):3826–33. https://doi.org/10.1200/JCO.2015.63.0319.

Article  PubMed  Google Scholar 

Singh H, Hurria A, Klepin HD. Progress through collaboration: an ASCO and U.S. Food and Drug Administration Workshop to improve the evidence base for treating older adults with cancer. Am Soc Clin Oncol Educ Book. 2018;23(38):392–9. https://doi.org/10.1200/EDBK_201133.

Article  Google Scholar 

Jia H, Lubetkin EI. Life expectancy and active life expectancy by disability status in older U.S. adults. PLoS One. 2020;15(9):e0238890. https://doi.org/10.1371/journal.pone.0238890.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86. https://doi.org/10.1002/cncr.26646.

Article  PubMed